University of Pennsylvania

GLP‑1 market, usage, safety & new guidance

182 clusters · 652 sources · last updated 1 day ago

Latest: Brazil's SUS delays rollout of GLP‑1 weight‑loss drugs

GLP‑1 receptor agonists dominate modern obesity and diabetes therapy, now reaching primary‑care, tele‑health and Medicare, with the market projected near $105 bn by 2030. Safety monitoring confirms a modest alopecia sign

PMOS Renaming – Heart, Fertility & Mental Health

19 clusters · 111 sources · last updated 1 day ago

Latest: Polyendocrine Metabolic Ovarian Syndrome Linked to Cardiovascular Risk in Women with Type 1 Diabetes

Following the May 2026 consensus to rename polycystic ovary syndrome as polyendocrine metabolic ovarian syndrome (PMOS) – later expanded to PC O AS – health agencies worldwide have begun embedding routine metabolic, card

Polish health advice on weight loss and sleep

2 clusters · 8 sources · last updated 4 days ago

Latest: Polish Health Guidance on Weight Loss and Insomnia

In late July 2026, Polish media began publishing a series of health‑focused pieces. The first article (25 July) offered a range of lifestyle tips: adding cinnamon and ginger to coffee to aid metabolism, a promotional cof

GLP‑1 weight‑loss drugs linked to hair loss

2 clusters · 12 sources · last updated 4 days ago

Latest: Ozempic and Wegovy linked to increased hair loss

A study released on 24 July 2026 examined over 50,000 health records and found that users of the GLP‑1 medications semaglutide (Wegovy) and tirzepatide (Mounjaro) faced a markedly higher risk of alopecia—up to 70 % great

AI integration in education

2 clusters · 5 sources · last updated 7 days ago

Latest: AI teaching assistants reduce student motivation in Turkish high schools

In late July 2026, the Slovak Ministry of Education announced that artificial‑intelligence tools could help teachers draft outlines for group projects, generate rubrics and produce reflective questions, provided that stu